树突细胞在肿瘤免疫治疗中的研究进展  

Research progress of dendritic cell for malignant tumors therapy

作　　者：王文湛[1] 双卫兵[1] WANG Wen-Zhan;SHUANG Wei-Bing(The First Hospital of Shanxi Medical University, Taiyuan 030001,China)

机构地区：[1]山西医科大学第一医院,山西太原030001

出　　处：《转化医学电子杂志》2017年第10期62-65,共4页E-Journal of Translational Medicine

基　　金：山西省高校2014年度131领军人才项目(晋教财【2015】41号165)

摘　　要：随着基因技术、分子生物学以及免疫学的快速发展,抗肿瘤免疫疗法也逐渐被视为是一种有效的肿瘤治疗方法.在抗肿瘤免疫过程中,树突状细胞(DC)是最具潜力的抗原提呈细胞,在介导抗肿瘤免疫的过程中发挥着关键作用,其抗肿瘤免疫治疗的重要性也日益受到关注,有关研究也取得了较大的进展,在临床上也显示出了良好的应用前景.本文对以DC为基础的恶性肿瘤免疫治疗的现状及研究进展作了总结.With the rapid development of gene technology,molecular biology and immunology,tumor immunotherapy has been gradually accepted as an effective treatment.Dendritic cells(DCs)are the most potential antigen-presenting cells(APCs)playing a critical role in the induction of antitumor immunity.The antitumor immunity role of DCs has been paid more attention in recendy.The research of tumor immunotherapy mediated by DCs makes great progress,and the treatment related to DC shows well application prospect in antitumor immunity.This paper reviews the current status and development of dendritic cell for tumor immunotherapy in recent years.

关 键 词：树突状细胞 恶性肿瘤 免疫治疗 

分 类 号：R730.51[医药卫生—肿瘤]